Boehringer Ingelheim’s Senvelgo Received the EC Approval in Europe for the Treatment of Feline Diabetes
Shots:
- The EC approved Senvelgo (velagliflozin oral solution), a prescription medication to improve glycemic control in cats with diabetes mellitus
- Senvelgo reduces blood glucose levels & minimizes the risk of clinical hypoglycemia episodes, improving the clinical symptoms of diabetes in cats as soon as one week after starting treatment. The oral liquid solution can be given QD to cats directly into their mouths or with small amounts of food
- Senvelgo oral solution, a highly selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) will be available in Europe, has already received approval in Switzerland, Great Britain, the U.S & seeking regulatory approval in the ROW
Ref: Boehringer | Image: Boehringer
Related News:- Boehringer Ingelheim’s Senvelgo (velagliflozin) Receives the US FDA’s Approval as the First Oral Liquid Medication for Diabetes in Cats
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
